It is a healthcare private limited company based in Chennai, Tamil Nadu, India, established in 2019.
2019 | Chennai, Tamil Nadu, India | ActiveOncocare Healthworks & Molecular Engineering Private Limited, a active private limited company, was established on 06 March 2019 in Chennai, Tamil Nadu, India. Engaging in preventive health services within the healthcare sector, it holds CIN: U85100TN2019PTC127878. Registered under ROC Roc Chennai. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.
Its leadership includes Sambandam Shreedharan (Director), Usha Vijayaraghavan (Director), Chidambaram Mohanarekha (Director). Past directors included Sambandam Shreedharan, Mathurbootham Lakshmi, Usha Vijayaraghavan. Its latest AGM occurred on 30 November 2021, with the balance sheet filed on 31 March 2021. It is based at 62/7, ( 60/7) , 4Th Main Road Gandhi Nagar, Adyar, Chennai, Tamil Nadu, 600020.
U85100TN2019PTC127878
127878
06 March 2019
₹1.00 M
₹0.10 M
Roc Chennai
Unlisted
Active
Explore comprehensive insights into Oncocare Healthworks & Molecular Engineering Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sambandam Shreedharan | Director | 07 Aug 2019 | Current |
| Usha Vijayaraghavan | Director | 06 Mar 2019 | Current |
| Chidambaram Mohanarekha | Director | 14 Aug 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Dec 2020 | Past |
| Pramod Abcsdd | Director | 21 Aug 2019 | Past |
| Pramod Abcsdd | Director | 13 Dec 2021 | Past |
| Pramod Abcsdd | Additional Director | 30 Dec 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Oncocare Healthworks & Molecular Engineering Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2020, Oncocare Healthworks & Molecular Engineering had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Oncocare Healthworks & Molecular Engineering, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Oncocare Healthworks & Molecular Engineering, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncocare Healthworks & Molecular Engineering's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Oncocare Healthworks & Molecular Engineering Private Limited last Annual general meeting of members was held on 30 Nov 2021 as per latest MCA records. was documented.
Oncocare Healthworks & Molecular Engineering Private Limited has filed its annual Financial statements for the year ended 31 Mar 2021 with Roc Chennai. was recorded as a recent event.
Chidambaram Mohanarekha was appointed as a Director was appointed as a Director on 14 Aug 2020 & has been associated with this company since 5 years 3 months . was recorded as a recent event.
Sambandam Shreedharan was appointed as a Director was appointed as a Director on 07 Aug 2019 & has been associated with this company since 6 years 3 months . was recorded as a recent event.
Progress on Usha Vijayaraghavan was appointed as a Director was appointed as a Director on 06 Mar 2019 & has been associated with this company since 6 years 8 months . was documented.
Progress on Oncocare Healthworks & Molecular Engineering Private Limited was registered on 06 Mar 2019 with Roc Chennai & aged 6 years 8 months as per MCA records. was documented.
The CIN of Oncocare Healthworks & Molecular Engineering Private Limited is U85100TN2019PTC127878.
Oncocare Healthworks & Molecular Engineering Private Limited is headquartered at 62/7, ( 60/7) , 4Th Main Road Gandhi Nagar, Adyar, Chennai, Tamil Nadu, 600020.
Oncocare Healthworks & Molecular Engineering Private Limited was incorporated on 06 March 2019.
The current directors of Oncocare Healthworks & Molecular Engineering Private Limited are
The primary industry of Oncocare Healthworks & Molecular Engineering Private Limited is Healthcare.
Oncocare Healthworks & Molecular Engineering Private Limited is unlisted.
The authorized capital of Oncocare Healthworks & Molecular Engineering Private Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX